Novo Nordisk Stock Target Price and Analyst Consensus

NVO Stock  USD 90.59  2.51  2.85%   
The current analyst and expert consensus on Novo Nordisk is Buy, with 1 strong sell and 5 strong buy opinions. The current projected Novo Nordisk target price consensus is 114.68 with 11 analyst opinions. Check out Macroaxis Advice on Novo Nordisk to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
The most common way Novo Nordisk AS analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Novo Nordisk executives and customers to further validate their buy or sell advice. Novo Nordisk buy-or-sell recommendation module provides average expert sentiment on the projected Novo Nordisk AS target price to derive its highest and lowest estimates based on projected price volatility of 3.3718.
Lowest Forecast
104.36
Highest Forecast
127.29
Target Price
114.68
At this time, Novo Nordisk's Gross Profit is very stable compared to the past year. As of the 24th of February 2025, Operating Profit Margin is likely to grow to 0.46, while Pretax Profit Margin is likely to drop 0.22. At this time, Novo Nordisk's Net Debt is very stable compared to the past year. As of the 24th of February 2025, Retained Earnings is likely to grow to about 151.7 B, while Cash is likely to drop about 8.3 B.
  
It's important to approach Novo Nordisk's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.

Novo Nordisk Target Price Consensus

Novo target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Novo Nordisk's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   11  Buy
Strong BuyBuyHoldSellStrong SellStrong Buy45.5%Buy18.2%Hold18.2%Sell9.1%Strong Sell9.1%100%
Most Novo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Novo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Novo Nordisk AS, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Novo Nordisk Target Price Projection

Novo Nordisk's current and average target prices are 90.59 and 114.68, respectively. The current price of Novo Nordisk is the price at which Novo Nordisk AS is currently trading. On the other hand, Novo Nordisk's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Novo Nordisk Market Quote on 24th of February 2025

Low Price85.74Odds
High Price91.09Odds

90.59

Target Price

Analyst Consensus On Novo Nordisk Target Price

Low Estimate104.36Odds
High Estimate127.29Odds

114.6767

Historical Lowest Forecast  104.36 Target Price  114.68 Highest Forecast  127.29
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Novo Nordisk AS and the information provided on this page.

Novo Nordisk Analyst Ratings

Novo Nordisk's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Novo Nordisk stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Novo Nordisk's financials, market performance, and future outlook by experienced professionals. Novo Nordisk's historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

JavaScript chart by amCharts 3.21.152.02.02.02.05.05.04.04.02.02.04.03.01.01.01.01.01.01.00.00.0Three Month AgoTwo Month AgoOne Month AgoCurrent 12345
JavaScript chart by amCharts 3.21.15Strong Buy Buy Hold Sell Strong Sell

Average Consensus Estimates

JavaScript chart by amCharts 3.21.15BuyBuyBuyBuyThree Month AgoTwo Months AgoOne Month AgoCurrentStrong SellSellHoldBuyStrong Buy
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.

Steps to utilize Novo Nordisk price targets

Novo Nordisk's stock target price is an estimate of its future price, usually made by analysts. Using Novo Nordisk's target price to determine if it is a suitable investment can be done through the following steps:
  • Look at Novo Nordisk's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
  • Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
  • Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
  • Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Novo Nordisk's stock is likely to perform well.
  • Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Remember that stock target prices are just estimates and are subject to change. Therefore, using them as one factor in a larger investment strategy is essential rather than relying solely on them to make decisions.

Additional Novo Nordisk Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Novo Nordisk is a key component of Novo Nordisk valuation and have some predictive power on the future returns of a Novo Nordisk.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Novo Nordisk's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
85.5488.8892.22
Details
Intrinsic
Valuation
LowRealHigh
79.9495.9099.24
Details
Naive
Forecast
LowNextHigh
87.3690.7094.04
Details
Earnings
Estimates (0)
LowProjected EPSHigh
6.066.276.47
Details

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Artificial Intelligence Idea
Artificial Intelligence
Invested few shares
FinTech Idea
FinTech
Invested over 30 shares
Driverless Cars Idea
Driverless Cars
Invested over 60 shares
Banking Idea
Banking
Invested over 30 shares
Adviser Favorites Idea
Adviser Favorites
Invested few shares
Momentum Idea
Momentum
Invested over 60 shares
Automobiles and Trucks Idea
Automobiles and Trucks
Invested over 60 shares
Corona Opportunity Idea
Corona Opportunity
Invested few shares
Dividend Beast Idea
Dividend Beast
Invested over 60 shares
Chemicals Idea
Chemicals
Invested over 30 shares
ESG Investing Idea
ESG Investing
Invested few shares
Social Domain Idea
Social Domain
Invested over 20 shares
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out Macroaxis Advice on Novo Nordisk to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Trending Assets

HEPA
Hepion Pharmaceuticals
0.16  -0.01  -5.88 
RETA
Reata Pharmaceuticals
0.00  0.00  0.00 
REGN
Regeneron Pharmaceuticals
713.25  12.92  1.84 
SRPT
Sarepta Therapeutics
105.56  -0.72  -0.68 
BMRN
Biomarin Pharmaceutical
69.01  0.76  1.11 
TGTX
TG Therapeutics
29.02  -1.86  -6.02 
NTLA
Intellia Therapeutics
11.51  -0.66  -5.42 
SGEN
Seagen Inc
0.00  0.00  0.00 
MRNA
Moderna
33.90  -1.63  -4.59 
TERN
Terns Pharmaceuticals
3.73  -0.28  -6.98 
VRTX
Vertex Pharmaceuticals
481.65  0.00  0.00 
DNA
Ginkgo Bioworks Holdings
10.46  -0.36  -3.33 
CVAC
CureVac NV
3.27  -0.03  -0.91 
NVAX
Novavax
7.41  -0.58  -7.26 
ALNY
Alnylam Pharmaceuticals
248.94  -1.65  -0.66 
ICPT
Intercept Pharmaceuticals
0.00  0.00  0.00 
BNTX
BioNTech SE
116.98  -3.03  -2.52 
MDGL
Madrigal Pharmaceuticals
322.14  -14.09  -4.19 
CRSP
Crispr Therapeutics
46.57  -1.34  -2.8